Binding of RAGE and RIPK1 induces cognitive deficits in chronic hyperglycemia‐derived neuroinflammation

Abstract Aims Chronic hyperglycemia‐induced inflammation of the hippocampus is an important cause of cognitive deficits in diabetic patients. The receptor for advanced glycation end products (RAGE), which is widely expressed in the hippocampus, is a crucial factor in this inflammation and the associated cognitive deficits. We aimed to reveal the underlying mechanism by which RAGE regulates neuroinflammation in the pathogenesis of diabetes‐induced cognitive impairment. Methods We used db/db mice as a model for type 2 diabetes to investigate whether receptor‐interacting serine/threonine protein kinase 1 (RIPK1), which is expressed in microglia in the hippocampal region, is a key protein partner for RAGE. GST pull‐down assays and AutoDock Vina simulations were performed to identify the key structural domain in RAGE that binds to RIPK1. Western blotting, co‐immunoprecipitation (Co‐IP), and immunofluorescence (IF) were used to detect the levels of key proteins or interaction between RAGE and RIPK1. Cognitive deficits in the mice were assessed with the Morris water maze (MWM) and new object recognition (NOR) and fear‐conditioning tests. Results RAGE binds directly to RIPK1 via the amino acid sequence (AAs) 362–367, thereby upregulating phosphorylation of RIPK1, which results in activation of the NLRP3 inflammasome in microglia and ultimately leads to cognitive impairments in db/db mice. We mutated RAGE AAs 362–367 to reverse neuroinflammation in the hippocampus and improve cognitive function, suggesting that RAGE AAs 362–367 is a key structural domain that binds directly to RIPK1. These results also indicate that hyperglycemia‐induced inflammation in the hippocampus is dependent on direct binding of RAGE and RIPK1. Conclusion Direct interaction of RAGE and RIPK1 via AAs 362–367 is an important mechanism for enhanced neuroinflammation in the hyperglycemic environment and is a key node in the development of cognitive deficits in diabetes.